Cyclacel increases authorized common shares from 250M to 600M; removes Series E conversion cap

Bio Green Med Solution, Inc.

Board and majority stockholder approved Certificate of Amendment filed April 25, 2025.
Authorized common stock increased from 250,000,000 to 600,000,000 shares; no change to issued shares.
Amended Series E Certificate of Designation removes the 4.99% ownership limitation on conversion and voting.
Removal of Series E cap allows unlimited conversion of preferred into common shares going forward.
Both amendments effective upon filing with Delaware Secretary of State on April 25, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bio Green Med Solution, Inc.: Increased authorized common stock from 250,000,000 to 600,000,000 shares (effective 2025-04-25).

Change: charter amendment
Effective: 2025-04-25

Exact text from the filing

The Certificate of Amendment increased the number of authorized shares of the Company’s common stock from two hundred fifty million (250,000,000) to six hundred million (600,000,000).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bio Green Med Solution, Inc.: Removed the Series E Ownership Limitation on conversion and voting of Series E Convertible Preferred Stock (effective 2025-04-25).

Change: charter amendment
Effective: 2025-04-25

Exact text from the filing

The Restated Certificate of Designation removes such Series E Ownership Limitation so that the shares of Series E Convertible Preferred Stock may be converted and voted without regard to such Series E Ownership Limitation.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-006201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.